Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study.
Hizal M, Bilgin B, Paksoy N, Açıkgöz Ö, Sezer A, Gürbüz M, Ak N, Yücel Ş, Ayhan M, Erol C, Demirkıran A, Mandel NM, Shbair A, Gökmen İ, Başoğlu T, Paydaş S, Demiray AG, İriağaç Y, Şakalar T, Zeynelgil E, Tatlı AM, Bahçeci A, Güven DC, Caner B, Can A, Gülmez A, Karakaş Y, Yalçın B, Demirkazık A, Bilici A, Aydıner A, Yumuk PF, Şendur MAN. Hizal M, et al. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7. Epub 2021 Jul 31. J Cancer Res Clin Oncol. 2022. PMID: 34331582
Do all aromatase inhibitors have similar efficacy and safety?
Şendur MA, Bilgin B, Hızal M, Özdemir NY, Akıncı MB, Dede DŞ, Yalçın B. Şendur MA, et al. Among authors: hizal m. Future Oncol. 2017 Aug;13(19):1673-1676. doi: 10.2217/fon-2017-0228. Epub 2017 Aug 23. Future Oncol. 2017. PMID: 28831832 No abstract available.
Adjuvant Capecitabine for Breast Cancer.
Hizal M, Şendur MAN, Yalçin B. Hizal M, et al. N Engl J Med. 2017 Aug 24;377(8):791. doi: 10.1056/NEJMc1708487. N Engl J Med. 2017. PMID: 28834475 No abstract available.
An update on immunotherapy options for urothelial cancer.
Bilgin B, Sendur MAN, Hizal M, Yalçın B. Bilgin B, et al. Among authors: hizal m. Expert Opin Biol Ther. 2019 Dec;19(12):1265-1274. doi: 10.1080/14712598.2019.1667975. Epub 2019 Sep 17. Expert Opin Biol Ther. 2019. PMID: 31518156 Review.
75 results